The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis
Open accessAbstract
Background: Intestinal fibrosis and subsequent stricture formation represent frequent complications of Crohn's disease (CD). In many organs, fibrosis develops as a result of epithelial to mesenchymal transition (EMT). Recent studies suggested that EMT could be involved in intestinal fibrosis as a result of chronic inflammation. Here, we investigated whether EMT might be involved in stricture formation in CD patients. Methods: Human colonic tissue specimens from fibrotic areas of 18 CD and 10 non‐IBD control patients were studied. Immunohistochemical staining of CD68 (marker for monocytes/macrophages), transforming growth factor‐β 1 (TGFβ 1), β‐catenin, SLUG, E‐.cadherin, α‐smooth muscle actin and fibroblast activation protein (FAP) were performed using standard techniques. Results: In fibrotic areas in the intestine of CD patients, a large number of CD68‐positive mononuclear cells was detectable suggesting an inflammatory character of the fibrosis. We found stronger expression of TGFβ 1, the most powerful driving force for EMT, in and around the fibrotic lesions of CD patients than in non‐IBD control patients. In CD patients membrane staining of β‐catenin was generally weaker than in control patients and more cells featured nuclear staining indicating transcriptionally active β‐catenin, in fibrotic areas. In these regions we also detected nuclear localisation of the transcription factor, SLUG, which has also been implicated in EMT pathogenesis. Adjacent to the fibrotic tissue regions, we observed high levels of FAP, a marker of reactive fibroblasts. Conclusions: We demonstrate the presence of EMT‐associated molecules in fibrotic lesions of CD patients. These findings support the hypothesis that EMT might play a role for the development of CD‐associated intestinal fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“EMT is also a crucial process that can elicit fibrosis in Crohn's disease and graft loss after kidney transplantation”
From Redox control of senescence and age-related disease. (2017) · cites this paper as [108]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 2×
“EMT is a common process that plays a pivotal role for embryogenesis, organ development, tissue regeneration and wound healing [9,10].”
BackgroundComplex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958 · cited 14×
“In particular, fibrotic areas revealed significantly more fibroblasts being αSMA-positive as well as being positive for both, the epithelial cell marker E-cadherin and the fibroblast marker, fibroblast-specific protein 1 (FSP1) [8].”
BackgroundInfluentialThe Versatile Role of microRNA-30a in Human Cancer
Wang, C., Yang, X., Chen, Y., & Chen, L. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000471111 · Cited by 3,409
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649 · cited 3×
“Though EMT has already been associated with the pathogenesis of fibrosis in many systems, such as kidney, liver or lung [11], the evidence for EMT being involved in the development of intestinal fibrosis in CD patients is lacking.”
BackgroundTGF-β and epithelial-to-mesenchymal transitions
Zavadil, J., & Böttinger, E. P. (2005) · Oncogene · doi:10.1038/sj.onc.1208927 · Cited by 1,578
Long-Term Evolution of Disease Behavior of Crohn's Disease
Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R., & Gendre, J.-P. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200207000-00002 · Cited by 1,346 · cited 1×
“Background Though most of IBD patients initially present with an inflammatory pathology, due to the longstanding and chronically relapsing disease, severe complications, such as stenosis, strictures or fistulae occur [1].”
BackgroundMolecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins
Holness, C., & Simmons, D. (1993) · Blood · doi:10.1182/blood.v81.6.1607.1607 · Cited by 733
DIRECT EVIDENCE FOR A ROLE OF β‐CATENIN/LEF‐1 SIGNALING PATHWAY IN INDUCTION OF EMT
Kim, K., Lu, Z., & Hay, E. D. (2002) · Cell Biology International · doi:10.1006/cbir.2002.0901 · Cited by 428 · cited 2×
“Further, activated SLUG as well as activated (meaning nuclear) β-catenin play an important role for the downregulation and disassembling of E-cadherin [12,15,18-20].”
BackgroundTargeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice
Santos, A. M., Jung, J., Aziz, N., Kissil, J. L., & Puré, E. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38988 · Cited by 428 · cited 1×
“A recent study even suggested that FAP inhibition might be beneficial for treating epithelial-derived tumours, since pharmacologic targeting of FAP inhibited tumour stromagenesis by affecting integrin-mediated signalling and led to a decreased recruitment and overall number of myofibroblasts [27].”
BackgroundIntestinal fibrosis in IBD—a dynamic, multifactorial process
Rieder, F., & Fiocchi, C. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.31 · Cited by 343 · cited 2×
“medications, are not effective in preventing fibrosis and that no specific anti-fibrotic medical therapy exists [4].”
Background
Cited by
Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases
Rieder, F., Fiocchi, C., & Rogler, G. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.047 · Cited by 529
Self-citationThe Role of Monocytes and Macrophages in Autoimmune Diseases: A Comprehensive Review
Ma, W.-T., Gao, F., Gu, K., & Chen, D.-K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01140 · Cited by 361
“CD patients, consistent with the potent tissue-repairing and profibrotic capacity of M2 Mφ (311, 312).”
ResultRedox control of senescence and age-related disease.
Chandrasekaran, A., Idelchik, M. D. P. S., & Melendez, J. A. (2017) · Redox Biology · doi:10.1016/j.redox.2016.11.005 · Cited by 360
“elicit fibrosis in Crohn's disease and graft loss after kidney transplantation [107,108].”
BackgroundVimentin Diversity in Health and Disease
Danielsson, F., Peterson, M. K., Caldeira Araújo, H., Lautenschläger, F., & Gad, A. K. B. (2018) · Cells · doi:10.3390/cells7100147 · Cited by 265
“Upregulation of vimentin is a canonical marker for EMT [206], as mesenchymal cells are vimentin dominated [207], and the expression of vimentin promotes the transformation of cells to a flatter, elongated, mesenchymal shape [165].”
BackgroundInfluentialFibroblasts and myofibroblasts of the intestinal lamina propria in physiology and disease
Roulis, M., & Flavell, R. A. (2016) · Differentiation · doi:10.1016/j.diff.2016.05.002 · Cited by 209
Metadata
- Authors
- Scharl, M., Huber, N., Lang, S., Fürst, A., Jehle, E., & Rogler, G.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Caritas-Krankenhaus St. Josef (DE)
- Department of Surgery Oberschwaben‐Klinik Ravensburg Germany
- Corresponding author
- Scharl, Michael
- Venue
- Clinical and Translational Medicine
- Publisher
- Wiley
- Published
- 2015-02-07
- Volume
- 4
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2001-1326 (ISSN-L)
- PMC
- PMC4384762
- OpenAlex
- W2154570785
- Cited by
- 118
- References
- 28
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 14 · 2023: 9 · 2022: 10 · 2021: 17 · 2020: 12 · 2019: 10 · 2018: 14 · 2017: 8 · 2016: 10 · 2015: 4
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (vor)
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Clinical and Translational Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (146204, 314730)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- epithelial-mesenchymal transition, Crohn's disease, intestinal fibrosis, intestinal stenosis, TGF-β1, β-catenin, Slug, fibroblast activation protein, CD68, colonic inflammation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis. https://app.cochat.ai/papers/10.1186/s40169-015-0046-5
- The paper
- Scharl, M., Huber, N., Lang, S., Fürst, A., Jehle, E., & Rogler, G. (2015). Hallmarks of epithelial to mesenchymal transition are detectable in Crohn's disease associated intestinal fibrosis. Clinical and Translational Medicine. https://doi.org/10.1186/s40169-015-0046-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.